After RBC Capital and Robert W. Baird gave Charles River Labs (NYSE: CRL) a Buy rating last month, the company received another Buy, this time from Jefferies. Analyst David Windley reiterated a Buy rating on Charles River Labs yesterday and set a price target of $145. The company’s shares closed yesterday at $124.18.
According to TipRanks.com, Windley is a top 25 analyst with an average return of 22.3% and a 79.9% success rate. Windley covers the Services sector, focusing on stocks such as WellCare Health Plans, PRA Health Sciences, and IQVIA Holdings Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Charles River Labs with a $136.80 average price target, implying a 10.2% upside from current levels. In a report released yesterday, Robert W. Baird also reiterated a Buy rating on the stock with a $133 price target.
.
See today’s analyst top recommended stocks >>
Charles River Labs’ market cap is currently $5.95B and has a P/E ratio of 46.86. The company has a Price to Book ratio of 5.22.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.
